Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

被引：49

作者：

Bakht M.K. ^{[1
,2
,3
]}

Oh S.W. ^{[1
,2
]}

Youn H. ^{[1
,2
]}

Cheon G.J. ^{[1
,2
]}

Kwak C. ^{[4
]}

Kang K.W. ^{[1
,2
]}

机构：

[1] Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul

[2] Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul

[3] Department of Biological Sciences, University of Windsor, Windsor, N9B 3P4, ON

[4] Department of Urology, Seoul National University College of Medicine, Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2017年 / 51卷 / 3期

关键词：

Antiandrogens; Molecular imaging; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen;

D O I：

10.1007/s13139-016-0439-4

中图分类号：

学科分类号：

摘要：

Prostate-specific membrane antigen (PSMA) is an attractive target for both diagnosis and therapy because of its high expression in the vast majority of prostate cancers. Development of small molecules for targeting PSMA is important for molecular imaging and radionuclide therapy of prostate cancer. Recent evidence implies that androgen-deprivation therapy increase PSMA-ligand uptake in some cases. The reported upregulations in PSMA-ligand uptake after exposure to second-generation antiandrogens such as enzalutamide and abiraterone might disturb PSMA-targeted imaging for staging and response monitoring of patients undergoing treatment with antiandrogen-based drugs. On the other hand, second-generation antiandrogens are emerging as potential endoradio-/chemosensitizers. Therefore, the enhancement of the therapeutic efficiency of PSMA-targeted theranostic methods can be listed as a new capability of antiandrogens. In this manuscript, we will present what is currently known about the mechanism of increasing PSMA uptake following exposure to antiandrogens. In addition, we will discuss whether these above-mentioned antiandrogens could play the role of endoradio-/chemosensitizers in combination with the well-established PSMA-targeted methods for pre-targeting of prostate cancer. © 2016, Korean Society of Nuclear Medicine.

引用

页码：202 / 211

页数：9

共 67 条

[11]

Lutje S., Heskamp S., Cornelissen A.S., Poeppel T.D., van den Broek S.A., Rosenbaum-Krumme S., Et al., PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status, Theranostics, 5, pp. 1388-1401, (2015)

[12]

Vargas H., Grimm J., Donati F.O., Sala E., Hricak H., Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm, Eur Radiol, 25, pp. 1294-1302, (2015)

[13]

Vallabhajosula S., Jhanwar Y., Tagawa S., Epstein J., Babich J., Youn T., Et al., 99m Tc-MIP-1404 Planar and SPECT scan: Imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression, J Nucl Med, 57, (2016)

[14]

Giesel F.L., Fiedler H., Stefanova M., Sterzing F., Rius M., Kopka K., Et al., PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, pp. 1794-1800, (2015)

[15]

Afshar-Oromieh A., Avtzi E., Giesel F.L., Holland-Letz T., Linhart H.G., Eder M., Et al., The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, pp. 197-209, (2015)

[16]

Ebenhan T., Vorster M., Marjanovic-Painter B., Wagener J., Suthiram J., Modiselle M., Et al., Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients, Molecules, 20, pp. 14860-14878, (2015)

[17]

Sterzing F., Kratochwil C., Fiedler H., Katayama S., Habl G., Kopka K., Et al., 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 43, pp. 34-41, (2016)

[18]

Kratochwil C., Giesel F.L., Eder M., Afshar-Oromieh A., Benesova M., Mier W., Et al., 177Lu Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer, Eur J Nucl Med Mol Imaging, 42, 6, pp. 987-988, (2015)

[19]

Afshar-Oromieh A., Hetzheim H., Kratochwil C., Benesova M., Eder M., Neels O.C., Et al., The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions, J Nucl Med, 56, pp. 1697-1705, (2015)

[20]

Delker A., Fendler W.P., Kratochwil C., Brunegraf A., Gosewisch A., Gildehaus F.J., Et al., Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer, Eur J Nucl Med Mol Imaging, 43, pp. 42-51, (2016)

← 1 2 3 4 5 6 7 →